MARIPOSA: This phase III trial is trying to understand how well three targeted cancer drugs work on their own or together to treat patients with EGFR+ non-small cell lung cancers that have spread to other parts of the bodyA Phase 3, Randomized Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib Versus Lazertinib as First-Line Treatment in Patients With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer.

Summary

Eligible patients will be randomised into Arm A, Arm B or Arm C of the trial, receiving different combinations of treatment depending on which Arm they are assigned. Patients in Arm A will receive intravenous Amivantamab at a dose adjusted to their body weight, once weekly in Cycle 1 and then every 2 weeks in subsequent cycles. These patients (in Arm A) will also receive an oral dose of Lazertinib (240mg) once daily. Patients in Arm B will receive an oral dose of Osimertinib (80mg), plus a Lazertinib-matching placebo (240mg) once daily. Patients in Arm C will receive oral Lazertinib (240mg), plus an Osimertinib-matching placebo (80mg) once daily.

Conditions

This trial is treating patients with non-small cell lung cancer.

More information